A press release yesterday on marketwatch.com reports that Eli Lilly and Company announced expected performance for 2014. Fourth quarter and full 2013 results are expected to be announced at the end of January and are expected to remain unchanged. According to John C. Lechleiter the chairman, president and CEO, the strategic focus continues to be on three main areas: replenishing and advancing their pipeline of new medicines, sustaining strong performance of currently marketed brands, and driving productivity gains to allow funding of R&D, launch of products and shareholder dividends.
Expiration of patents including Cymbalta® and Evista® (this March) is expected to substantially reduce sales on those lines but other patented lines such as Cialis®, Humalog ® and Trajenta® are expected to show growth to help offset these losses. Revenue is expected to be the in the range of $19.2 to $19.8 billion. Earnings per share of $2.77 to $2.85 are expected for 2014. Thirteen potential new medicines are in Phase III development or submission stage. A gross margin of 74 percent is expected in 2014. A decrease in operating expenses is expected. R&D expenses are expected to be 4.4 to $4.7 billion. Net income of $3 billion and cash flow of $4 billion are expected. A webcast of the conference call can be found online at Lilly’s website.